COR MINUTES

To: COR Members
From: Jeanne Hossenlopp
Date: 3/7/12
Re: Marquette University Committee on Research
Approved Minutes/ March 7, 2012 Meeting

Present: David Clark, Richard Friman, Arthur Hefti, Jeanne Hossenlopp, Kyle Kim, Doug Lobner, Tim McMahon, William Pink, Raj Rathore, Erik Ugland, Marianne Weiss

Excused: David Papke

Also Present: Melody Baker (note taker), Amanda Ahrndt (ORC), Kathy Durben (ORSP), Tim Melchert (Grad School)

The meeting was called to order by Dr. Lobner at 9:00 a.m. The agenda was approved.

Reports:
Report from the Vice Provost for Research
Dr. Hossenlopp described an agreement that was reached concerning F&A rates at a recent meeting with Mel Austin. This will still need the approval of the provost so more details are to come.

After his meeting with the COR last month Fr. Pilarz requested that time be scheduled at the May Board of Trustees to discuss research. Dr. Hossenlopp will be working with the provost to plan this meeting.

Mr. Ben Kennedy has accepted the position of Research Compliance Office, Human Subjects and Radiations Safety and will start later this month.

Lastly, Dr. Hossenlopp shared a handout on NSF expenditures, discussed past reports, and explained how reporting has been improved.

Report from the Chair – no report

Report from the Director of ORSP
Ms. Durben reported on year-to-date awards in comparison with last year, as well as February submissions, which included seven new NSF applications, and announced new awards that were received.

At a recent meeting with associate deans, research efforts and goals were discussed.

Lastly, the IPRB met and will be submitting an updated policy to the COR for review.

Report from ORC
Ms. Ahrndt shared a handout and briefly discussed charts on protocols activities, which show a marked increase in workload for the ORC.

Business:

*Follow-up on Conflict of Interest Policy*

Per Ms. Durben, the policy is still being reviewed and will be brought to the COR next month.

*Travel Funds*

Brought up at the last COR meeting by Fr. Pilarz, this topic has been delegated to the provost, who is looking for some input from the COR - i.e. - what can it be used for? Comments and ideas included:

- Use the same guidelines for FDA’s with some additional options for use such as conference travel when presentations are *not* being made.
- Require the applicant to request for matching funds from the department or college. If a department does not have money to match, that should be stated and exceptions should be made. (Department funds should be exhausted first)
- International travel is very important, but difficult due to lack of funds in some departments.
- Give preference to associate faculty who need to boost their careers. Junior faculty are expected to make presentations to advance.
- Clinical and adjunct faculty currently have *no* access to funds. A suggestion was made to split the funds to share with them.
- Applicants should be required to submit a plan (why needed, how it will help their career) and report afterwards.
- Who will read the applications and make decisions?
- What is the goal of the fund (increase number of people going on trips, or decrease out of pocket cost to trips already planned)? A clear purpose and guidelines are needed.
- Add funds to the RRG to allow travel for research presentations by adding an additional line item to the RRG budget.
- Is the $100K a one-time fund, to be spent in FY13, or a permanent fund?
- Add the fund to the FDA’s under Dr. H’s purview.

*Updating Marquette’s FWA (Federal Wide Assurance)*

Dr. Hossenlopp discussed what is required to be reported regarding human subjects research, and what could be optional. The implications of opting out of reporting research that is not federally funded was discussed. If there is non-compliance, it will need to be handled by MU and a process needs to be in place for such instances. The IRB will need to suspend non-compliant protocols with back up by the IO and the support of the deans. Regulations need to be drafted.

*Follow-up to Fr. Pilarz’ discussion*
Dr. Lobner described the two main points of discussion with Fr. Pilarz last month: 1) faculty need to attend a special meeting with the BOT to discuss research, 2) more involvement with advancement is need to help raise research funds.

At this point it is unclear how the strategic planning will proceed; Dr. Hossenlopp said most strategic plans include a SWOT analysis (strengths, weaknesses, opportunities, and threats) and suggested this could be a starting point. It was agreed that funds needed for new hires should be a top priority. Dr. Hossenlopp advocated for doing a better job of listing strengths also.

Other

Dr. Hefti announced that the CTSI is offering a full day workshop on Drug Development and Repurposing on May 30th. More information to come.

The meeting adjourned at 10:15am.